3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Sarcoma
3
Insulin-Like Growth Factor I, Resistance To
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Pleural Effusion, Malignant
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Jaundice
1
Gastrointestinal Neoplasms
1
Endocrine Gland Neoplasms
1
Carcinoid Tumor
1
Askin Tumor
1
Interventions
Gemcitabine
4
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
napabucasin
2
entinostat
2
Ocoxin
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
niraparib
1
irinotecan sucrosofate
1
ganitumab
1
Trabectedin
1
Taxes
1
Paclitaxel
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Dexamethasone
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endocrine Gland Neoplasms
×
ganitumab
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts